Dulaglutide improved heart function more than exenatide in rats with metabolic syndrome, both protecting against heart attack damage through antioxidant mechanisms.
7% ejection fraction improvementDulaglutide improved heart ejection fraction by 7 percentage points in rats with metabolic syndrome, more than double exenatide's 3% improvement
What the researchers found
After 6 weeks of treatment in rats with metabolic syndrome:
- Exenatide improved ejection fraction by 3% vs untreated MetS group
- Dulaglutide improved ejection fraction by 7% vs untreated MetS group
- Histology showed reduced cardiomyocyte cross-sectional area: 11% reduction with exenatide, 18% with dulaglutide
- Both drugs reduced oxidative stress biomarkers
- Dulaglutide showed a slight advantage overall
Why it matters
People with metabolic syndrome have higher risk of heart attacks and worse outcomes when they occur. GLP-1 drugs are prescribed for diabetes and weight loss in this population. Evidence that they also protect the heart during a heart attack would be a major additional benefit. This animal study provides mechanistic support for the cardiovascular benefits seen in human clinical trials.
The numbers in context
- 24 rats in 3 groups (8 per group)
- Exenatide dose: 5 μg/kg
- Dulaglutide dose: 0.6 mg/kg
- Treatment duration: 6 weeks
- Ejection fraction improvement: 3% (exenatide), 7% (dulaglutide)
- Cardiomyocyte area reduction: 11% (exenatide), 18% (dulaglutide)
How the study worked
24 Wistar albino rats were given metabolic syndrome through diet. They were divided into three groups: untreated MetS, exenatide-treated (5 μg/kg), and dulaglutide-treated (0.6 mg/kg). After 6 weeks, heart function was assessed by echocardiography in living animals. Hearts were then removed and subjected to simulated ischemia-reperfusion injury using a Langendorff apparatus. Tissue was analyzed histologically and for oxidative stress biomarkers.
Who was studied
24 Wistar albino rats with diet-induced metabolic syndrome
What this study cannot tell us
Tested in rats with diet-induced metabolic syndrome, not humans. The simulated heart attack (Langendorff) is a simplified model. The MetS model may not replicate all features of human metabolic syndrome. Only 8 rats per group limits statistical power. The treatment was given before the heart attack (pretreatment), not after. The 6-week duration may not capture long-term effects.
How to read the evidence
Rated preliminary: small animal study (24 rats) using a simplified heart attack model. Results need validation in larger animal studies and humans.
When this study was published
Published in 2024. Adds to preclinical evidence for GLP-1 cardioprotection that complements large human cardiovascular outcome trials.
The bigger picture
People with metabolic syndrome have higher heart attack risk and worse outcomes. GLP-1 drugs are prescribed for diabetes and weight loss in this population. Evidence of additional heart protection supports their use.
Questions still open
- Why did dulaglutide outperform exenatide?
- Would semaglutide or tirzepatide show even stronger cardioprotection?
Common questions
Do GLP-1 drugs protect the heart during heart attacks?
How do GLP-1 drugs protect the heart?
Read the original research
Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome.
Pharmaceuticals (Basel, Switzerland), 17(4)
Citation
Ravic, Marko; Srejovic, Ivan; Novakovic, Jovana; Andjic, Marijana; Sretenovic, Jasmina; Muric, Maja; Nikolic, Marina; Bolevich, Sergey; Alekseevich Kasabov, Kirill; Petrovich Fisenko, Vladimir; Stojanovic, Aleksandra; Jakovljevic, Vladimir. (2024). Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome.. Pharmaceuticals (Basel, Switzerland), 17(4). https://doi.org/10.3390/ph17040525